Oncocyte Corp financial data

Symbol
OCX on Nasdaq
Location
15 Cushing, Irvine, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 189 % +6.94%
Debt-to-equity 692 % +326%
Return On Equity -767 % -437%
Return On Assets -96.9 % -90.9%
Operating Margin -1.52K % +47.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.6M shares +246%
Common Stock, Shares, Outstanding 28.6M shares +246%
Entity Public Float 24.6M USD +30.9%
Common Stock, Value, Issued 367M USD +18.3%
Weighted Average Number of Shares Outstanding, Basic 25.7M shares +211%
Weighted Average Number of Shares Outstanding, Diluted 25.7M shares +211%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.84M USD +178%
Cost of Revenue 1.75M USD +107%
Research and Development Expense 10.5M USD +10.3%
Selling and Marketing Expense 4.3M USD +46.1%
General and Administrative Expense 10.6M USD +1.94%
Operating Income (Loss) -58.6M USD -45.5%
Nonoperating Income (Expense) 368K USD +18.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -60.7M USD -144%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -58.2M USD -45.7%
Earnings Per Share, Basic -4 USD/shares +28.2%
Earnings Per Share, Diluted -4 USD/shares +28.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31M USD +456%
Accounts Receivable, after Allowance for Credit Loss, Current 3.54M USD +2099%
Inventory, Net 459K USD
Assets, Current 36.3M USD +455%
Property, Plant and Equipment, Net 6.8M USD +25.7%
Operating Lease, Right-of-Use Asset 4.04M USD +15.3%
Intangible Assets, Net (Excluding Goodwill) 14.6M USD -74.2%
Other Assets, Noncurrent 642K USD +46.6%
Assets 60.4M USD -15%
Accounts Payable, Current 2.28M USD +151%
Accrued Liabilities, Current 2.52M USD +4%
Liabilities, Current 9.68M USD +16.3%
Liabilities 50.1M USD -7.24%
Accumulated Other Comprehensive Income (Loss), Net of Tax 41K USD +2.5%
Retained Earnings (Accumulated Deficit) -357M USD -19.5%
Stockholders' Equity Attributable to Parent 10.2M USD -11.8%
Liabilities and Equity 60.4M USD -15%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.86M USD -53%
Net Cash Provided by (Used in) Financing Activities 28.6M USD
Net Cash Provided by (Used in) Investing Activities -307K USD -1179%
Common Stock, Shares Authorized 230M shares 0%
Common Stock, Shares, Issued 28.6M shares +246%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 22.4M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.1M USD -59%
Interest Paid, Excluding Capitalized Interest, Operating Activities 24K USD
Deferred Tax Assets, Valuation Allowance 64.4M USD -4.28%
Deferred Tax Assets, Gross 69.1M USD -16.4%
Operating Lease, Liability 2.41M USD
Depreciation 450K USD +56.8%
Payments to Acquire Property, Plant, and Equipment 307K USD +1179%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.2M USD -45.7%
Lessee, Operating Lease, Liability, to be Paid 2.74M USD -28.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 695K USD -41.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +3.32%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 328K USD -47.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 695K USD -22.7%
Deferred Tax Assets, Operating Loss Carryforwards 50M USD -19.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.1M USD -52.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 695K USD -22.7%
Operating Lease, Payments 281K USD +3.31%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 73K USD -17%
Depreciation, Depletion and Amortization 491K USD +46.6%
Deferred Tax Assets, Net of Valuation Allowance 4.68M USD -69.5%
Share-based Payment Arrangement, Expense 1.81M USD -22.9%